FDA Approves Eli Lilly's and Boehringer Ingelheim Pharmaceuticals' Triple-Combination Diabetes Drug Trijardy XRThe Motley Fool • 01/28/20
Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical TrialThe Motley Fool • 01/27/20
Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 01/22/20
Eli Lilly's Shopping Spree Won't Stop With Dermira, CFO Shares Plans For More Deals In 2020The Motley Fool • 01/17/20
Eli Lilly Releasing Cheaper Insulin Generic to Compete With Lispro ProductsThe Motley Fool • 01/14/20
Eli Lilly to Boost Its Dermatology Pipeline with $1.1 Billion Dermira AcquisitionThe Motley Fool • 01/10/20
Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To ExpectInvestors Business Daily • 01/09/20